Welcome to Entry Card of Lysosomal Enzymes


Details of RareLED ID Assay_1015
Primary information
GENECTSL1
NUMBER OF ASSAY169
ASSAY IDs360105 255214 1253921 257087 257086 51216 528188 273238 261374 1063747 1343001 747457 673910 460199 387652 219375 51359 51215 51214 723752 746599 331274 307166 288394 266478 262992 262988 254422 51221 51361 51223 691902 691777 609671 1063748 744931 367817 328996 321575 308312 277533 271489 263489 256977 254761 242864 242861 242467 242060 241928 238813 238799 51220 1241504 51348 51357 717411 570625 554254 493664 466813 1299799 699424 339653 51365 51350 1258331 1118859 1343919 365200 364998 364623 321239 314232 314221 308694 268737 264114 242445 240877 240723 238450 51360 51377 51362 51349 51222 51355 703432 677817 609674 569013 539533 526077 466516 470230 440410 430241 428163 351472 370556 361732 339478 321760 270168 51224 312630 290154 262164 260673 256974 242311 51363 1258203 1257961 1257954 1257556 1169039 1138573 1058728 668141 668139 668137 668134 569130 4403
Assay Name1. Inhibition of human recombinant cathepsin L after 10 mins,2. Apparent inhibitory constant against human cathepsin L,3. Inhibition of human liver cathepsin L using Z-FR-AMC as substrate measured every 15 sec for 5 mins by fluorescence assay,4. Inhibitory activity against human cathepsin L expressed in HepG2 cells,5. Inhibitory activity against human cathepsin L,6. In vitro inhibitory activity against human cathepsin L, using 2 uM of Z -Leu-Arg-AMC as substrate,7. Inhibition of human liver cathepsin L after 5 mins by microplate reader analysis,8. Inhibition of cathepsin L,9. Inhibition of human cathepsin L,10. Inhibition of recombinant human Cathepsin L using Z-Phe-Arg-aminomethylcoumarin as substrate preincubated for 30 mins followed by substrate addition,11. Inhibition Assay: Assay buffers consist of 20 mM citric acid, 60 mM disodium hydrogen orthophosphate, 1 mM EDTA, 0.1% CHAPS, 4 mM DTT, pH 5.8 for legumain, 50 mM dihydrogen sodium orthophosphate, 1 mM EDTA, 5 mM DTT, pH 6.25 for cathepsin B and cathepsin Land 100 mM Tris, 0.1% CHAPS, 10% sucrose, 10 mM DTT, pH 7.4 for caspase-3. Concentrations of substrates during the measurement were 10 nM (legumain, cathepsin Land caspase-3) and 50 nM (cathepsin B) and concentration of enzymes were 100 nM for cathepsin Land caspase-3, 270 nM for legumain and 360 nM for cathepsin B. Each enzyme was incubated with inhibitor concentrations ranging from 1 nM to 1 mM in the presence of the substrates.,12. Inhibition of cathepsin L (unknown origin) using Z-FR-AMC as substrate after 30 mins by fluorescence assay,13. Inhibition of human liver cathepsin L using Z-R-R-AMC as substrate preincubated with compound for 5 mins measured after 20 mins by fluorescence analysis,14. Inhibition of human liver cathepsin L,15. Inhibition of human recombinant cathepsin L by fluorometric assay,16. Inhibitory activity against Human cathepsin L,17. Inhibitory activity against human Cathepsin L,18. Compound was measured for inhibition of collagenolytic of human Cathepsin L,19. Compound was measured for inhibition of collagenolytic of human Cathepsin L,20. Competitive inhibition of human recombinant cathepsin L endopeptidase activity using Z-FR-AMC substrate expressed in Escherichia coli assessed as inhibition constant for enzyme-inhibitor complex,21. Inhibition of recombinant cathepsin-L (unknown origin) using Z-Phe-Arg-AMC as substrate by fluorescence assay,22. Inhibition of human cathepsin L,23. Inhibition of cathepsin L,24. Inhibition of cathepsin L,25. Inhibition of human cathepsin L,26. Inhibition of Cathepsin L,27. Potency against Cathepsin L in HepG2 cells by whole cell enzyme occupancy assay,28. Inhibitory concentration against recombinant human Cathepsin L at 37 degree C at pH 5.5,29. Inhibitory activity against recombinant human cathepsin L (cat L) expressed in baculovirus,30. Inhibitory activity against recombinant human cathepsin L,31. Inhibitory activity against recombinant human cathepsin L (1.2 nM),32. Inhibition of human cathepsin L using Z-Phe-Arg-pNA as substrate after 80 mins by spectrophotometric analysis,33. Inhibition of human cathepsin L using Z-Phe-Arg-pNA as substrate after 10 mins by spectrophotometric analysis,34. Inhibition of human cathepsin L using Z-Phe-Arg-AMC as substrate after 1 hr by fluorescence assay,35. Inhibition of recombinant human Cathepsin L using Z-Phe-Arg-aminomethylcoumarin as substrate,36. Inhibition of human liver Cathepsin L using Z-Phe-Arg-aminomethylcoumarin as substrate incubated for 5 mins prior to substrate addition measured for 5 mins by fluorometric analysis,37. Inhibition of human cathepsin L by fluorescence assay,38. Inhibition of human recombinant cathepsin L by fluorescence assay,39. Inhibition of cathepsin L,40. Inhibition of human cathepsin L,41. Inhibition of human recombinant cathepsin L,42. Inhibition of cathepsin L,43. Inhibition of Cathepsin L,44. Inhibitory constant against human cathepsin L using Z-Phe-Arg-AMC substrate,45. Inhibitory activity against cathepsin L from human,46. Apparent inhibitory constant against human cathepsin L,47. Apparent inhibitory constant against human cathepsin L,48. Inhibitory concentration against human cathepsin L by fluorescence assay using 5 uM Cbz-Phe-Arg-AMC,49. Inhibition of 5 uM Cbz-Phe-Arg-AMC human cathepsin L in fluorescence assay,50. Inhibitory concentration against human cathepsin L using 5 uM Cbz-Phe-Arg-AMC,51. Inhibition constant against human cathepsin L using Cbz-Phe-Arg-AMC,52. Inhibition constant against human cathepsin L using Cbz-Phe-Arg-AMC,53. Inhibition of recombinant human cathepsin L in a fluorescence assay.,54. Inhibition of human cathepsin-L using Z-Phe-Arg-AMC as substrate preincubated for 30 mins measured after 10 mins by fluorescence assay,55. Inhibitory concentration against recombinant human cathepsin L was determined in a fluorescence assay using 5 uM Cbz-Phe-Arg-AMC as substrate,56. Binding affinity of compound was evaluated against cathepsin L.,57. Inhibition of cathepsin L using FR-aminoluciferin as substrate preincubated for 15 mins before substrate addition measured after 1 hr by luminescence assay,58. Inhibition of human recombinant cathepsin L after 1 hr,59. Inhibition of human recombinant cathepsin L after 30 mins by spectrophotometric assay,60. Inhibition of human recombinant cathepsin L,61. Inhibition of cathepsin L,62. Inhibition of human liver cathepsin L using Cbz-Phe-Arg-pNA as substrate incubated for 30 mins measured for 20 mins by photometrical analysis,63. Inhibition of human recombinant CatL assessed as suppression of enzyme-mediated Z-Phe-Arg-AMC cleavage by QFRET assay,64. Inhibition of human recombinant cathepsin L by fluorescence assay,65. Inhibition of human Cathepsin L,66. Inhibition of human cathepsin L.,67. Biological Assay: Human liver Cathepsin L (Sigma) was preincubated with test compounds at various concentrations for 5 minutes at 25C. The assay was initiated by addition of substrate Z-Phe-Arg-aminomethylcoumarin (Z-F-R-AMC Bacchem) and the final assay conditions were 1 nM cathepsin L, 50 uM Z-F-R-AMC, 100 mM sodium acetate pH 5.5, 1 mM EDTA (Omnipure), 3 mM DTT (EMD), 0.01% BRIJ 35 (Sigma), and 2.0% DMSO (Acros). Test compounds were serially diluted with DMSO and water to include a final concentration range of 10 uM to 10 pM. The reaction was monitored fluorometrically for 5 minutes at 25C. using black 96-well Corning 3686 assay microplates with a Thermo Fluoroskan Ascent FL microplate reader at excitation and emission filter wavelengths of 355 nm and 460 nm, respectively.,68. Inhibition of human cathepsin L1,69. Cathepsin Enzyme Inhibition Assay: Enzyme activity is measured by observing the increase in fluorescence intensity caused by cleavage of a peptide substrate containing a fluorophore whose emission is quenched in the intact peptide. Assay buffer: 100 mM potassium phosphate pH 6.5, EDTA-Na 5 mM, Triton X-100 0.001%, DDT 5 mM. Enzymes (all at 1 nM): human and mouse Cathepsin S, Cat K, Cat B, Cat LSubstrate (20 uM): Z-Val-Val-Arg-AMC, except for Cat K which uses Z-Leu-Arg-AMC (both from Bachem). Z=Benzyloxycarbonyl. AMC=7-Amino-4-Methyl-Coumarin. Final volume: 100 uL. Excitation 360 nm, Emission 465 nm. Enzyme is added to the substance dilutions in 96-well microtitre plates and the reaction is started with substrate. Fluorescence emission is measured over 20 minutes, during which time a linear increase is observed in the absence of inhibitor.,70. Inhibition of human recombinant cathepsin L by fluorescence assay,71. Inhibition of human recombinant cathepsin L by fluorescence assay,72. Inhibition of human cathepsin L,73. Inhibition of human recombinant cathepsin L,74. Inhibition of cathepsin L in human HepG2 cells,75. Inhibition of cathepsin L,76. Inhibition of human cathepsin L,77. Inhibition of human cathepsin L,78. Inhibition of recombinant human cathepsin L,79. Inhibition of 5 lM Cbz-Phe-Arg-AMC bindign to human cathepsin L activity in fluorescence assay with 100 mM NaOAc,80. Inhibitory concentration against human liver cathepsin L,81. Inhibitory concentration against human cathepsin L,82. Tested for inhibitory effect on human liver cathepsin L,83. Inhibitory activity against human Cathepsin L,84. Inhibitory activity against cathepsin L (catL),85. Inhibitory activity was measured against Cathepsin L,86. Inhibition of Cathepsin L from human kidney,87. Inhibitory activity against recombinant human cathepsin L activity,88. Ability to block cathepsin L-catalyzed hydrolysis of the fluorogenic substrate Z-Phe-Arg-NHMec,89. Inhibition of human recombinant cathepsin-L using Z-Phe-Arg-AMC as substrate preincubated for 15 mins measured after 1 hr by QFRET assay,90. Inhibition of human recombinant cathepsin L using Z-Phe-Arg-AMC as substrate preincubated for 30 mins measured after 1 hr by quenched fluorescent resonance energy transfer assay,91. Inhibition of human recombinant cathepsin L using Z-LR-AMC as substrate by fluorescence assay,92. Activity at recombinant cathepsin L,93. Inhibition of human cathepsin L by fluorescence assay,94. Inhibition of human recombinant cathepsin L,95. Inhibition of human recombinant cathepsin L by fluorescence assay,96. Inhibition of human cathepsin L,97. Inhibition of human cathepsin L,98. Inhibition of cathepsin L assessed as inhibition of fluorogenic substrate cleavage,99. Inhibition of cathepsin L,100. Inhibition of cathepsin L,101. Inhibition of human recombinant cathepsin L by fluorescence assay,102. Inhibition of human recombinant cathepsin L by fluorometric assay,103. Inhibition of human recombinant cathepsin L,104. Inhibition of cathepsin L,105. Inhibition of Cathepsin L,106. Inhibitory activity tested against Human Cathepsin L using Z-Phe-Arg-pNA as substrate,107. Inhibition of human liver cathepsin L,108. Inhibition of human recombinant cathepsin L,109. Inhibition of cathepsin L,110. Inhibition of recombinant human cathepsin L in a fluorescence assay,111. Inhibitory activity against human cathep
ACTIVITYSubstance BioActivity: 10 Active, 6 Activity <= 1 µM, 12 Tested Substance BioActivity: 9 Active, 4 Activity <= 1 nM, 9 Activity <= 1 µM, 9 Tested Substance BioActivity: 12 Active, 8 Activity <= 1 µM, 15 Tested Substance BioActivity: 4 Active, 4 Activity <= 1 µM, 6 Tested Substance BioActivity: 6 Active, 2 Activity <= 1 µM, 6 Tested Substance BioActivity: 22 Active, 5 Activity <= 1 µM, 38 Tested Substance BioActivity: 11 Active, 8 Activity <= 1 µM, 25 Tested Substance BioActivity: 5 Tested Substance BioActivity: 13 Active, 3 Activity <= 1 nM, 13 Activity <= 1 µM, 13 Tested Substance BioActivity: 1 Active, 1 Activity <= 1 µM, 1 Tested Substance BioActivity: 1 Active, 3 Tested Substance BioActivity: 9 Active, 1 Activity <= 1 µM, 19 Tested Substance BioActivity: 18 Active, 12 Activity <= 1 µM, 36 Tested Substance BioActivity: 25 Active, 17 Activity <= 1 µM, 36 Tested Substance BioActivity: 11 Active, 9 Activity <= 1 µM, 12 Tested Substance BioActivity: 7 Active, 1 Activity <=